...frontotemporal lobar degeneration and other neurodegenerative diseases. Oncologie to test lead cancer therapy with Keytruda Oncologie...
...mAb against phosphatidylserine, in combination with Keytruda pembrolizumab in second-line gastric and gastroesophageal cancer patients. Oncologie...
...by Nan Fung Life Sciences and Pivotal bioVenture Partners China (see "$80M Series B Backs Oncologie's...

...in the cancer company's tranched $80 million series B. The funds are expected to push Oncologie...
...an additional in-licensing deal, look for the company to round out its pipeline this year. Oncologie...
...to $27.5 million, Oncologie President and CEO Laura Benjamin told BioCentury. In the year since, Oncologie...

...Mologen AG (Xetra:MGNK) and Oncologie Inc. (Cayman Islands) agreed on Aug. 17 to a three month...
...a deal granting Oncologie exclusive, worldwide rights to Mologen's lead compound lefitolimod (MGN1703). In February, Oncologie...
...cancer (SCLC). Mologen AG (Xetra:MGNK), Berlin, Germany Oncologie Inc., Cayman Islands Business: Cancer Shannon Lehnbeuter lefitolimod (MGN1703) Mologen AG Oncologie...

...partnered to develop biomarkers associated with Oncologie's immuno-oncology pipeline. The partners declined to disclose details. Oncologie...
...Molecular Diagnostics Inc. (NASDAQ:HTGM), Tuscon, Ariz. Oncologie Inc., Waltham, Mass. Business: Diagnostic Shannon Lehnbeuter HTG Molecular Diagnostics Inc. Oncologie...

...Cancer company Oncologie Ltd. (Cayman Islands) raised $16.5 million in a seed financing led by Pivotal...
...the round. Oncologie plans to develop in-licensed cancer assets in China and the U.S. simultaneously. Oncologie...
...p=0.006). Oncologie Ltd., Cayman Islands Jaime De Leon bavituximab (3G4, Tarvacin) lefitolimod (MGN1703) Avid Bioservices Inc. Mologen AG Phosphatidylserine Toll-like receptor 9 (TLR9) Oncologie...

...Cancer company Oncologie Ltd. (Cayman Islands) raised $16.5 million in a seed financing led by Pivotal...
...the round. Oncologie plans to develop in-licensed cancer assets in China and the U.S. simultaneously. Oncologie...
...to treat advanced solid malignancies in combination with anti-CTLA-4 mAb Yervoy ipilimumab. Early next year, Oncologie...

...Mologen AG (Xetra:MGN) granted Oncologie Ltd. (Cayman Islands) exclusive, global co-development rights and rights to develop...
...Mologen said the co-development portion of the deal will include leverage "novel biomarker plans from Oncologie."...
...lung cancer (SCLC). Mologen AG (Xetra:MGN), Berlin, Germany Oncologie Ltd., Cayman Islands Business: Cancer Shannon Lehnbeuter lefitolimod Mologen AG Oncologie...

...for $95 million in development, regulatory and commercialization milestones. Avid is also eligible for royalties. Oncologie...
...Avid Bioservices Inc. (NASDAQ:CDMO) Tustin, Calif. Oncologie Ltd., Cayman Islands Business: Cancer Shannon Lehnbeuter Avid Bioservices Inc. Oncologie...

...and John Felitti general counsel. Brandely was director of clinical development at the Pierre Fabre Oncologie...

...acquire Degussa subsidiary Asta Medica Oncologie (Frankfurt, Germany) for EUR525 million ($470 million). Asta Medica Oncologie...